Healthcare & Pharmaceuticals

Pfizer begins early-stage study of oral COVID-19 drug

3 minute read
1/3

A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" and medical sryinges are placed on a Pfizer logo in this illustration taken November 29, 2020. REUTERS/Dado Ruvic/Ilustration

Register now for FREE unlimited access to reuters.com

March 23 (Reuters) - Pfizer Inc (PFE.N) has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on Tuesday.

The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SA , said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies.

Pfizer's candidate, named PF-07321332, is a protease inhibitor that prevents the virus from replicating in cells.

Register now for FREE unlimited access to reuters.com

Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both on their own and in combination with other antivirals, the company said.

Pfizer believes this class of molecules may provide well-tolerated treatments against COVID-19, as currently marketed therapeutics that work on the same lines have not reported safety concerns.

The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients.

"Together, the two (oral and intravenous candidates) have the potential to create an end-to-end treatment paradigm that complements vaccination in cases where disease still occurs," Pfizer's Chief Medical Officer Mikael Dolsten said in a statement.

Pfizer's candidate is behind two other oral antiviral therapies, which are in mid-stage trials – the first being developed by rival Merck & Co (MRK.N) with Ridgeback Bio, and a second from Roche Holding (ROG.S) and Atea Pharmaceuticals. read more

Gilead Sciences' (GILD.O) remdesivir is currently the only U.S. Food and Drug Administration-approved drug for the treatment of COVID-19.

The FDA has granted an emergency authorization to intravenous therapies from Eli Lilly (LLY.N) - bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron (REGN.O).

Register now for FREE unlimited access to reuters.com
Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters